Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Proqr Therapeutics (PRQR)

Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,320
  • Shares Outstanding, K 81,355
  • Annual Sales, $ 7,050 K
  • Annual Income, $ -30,430 K
  • 60-Month Beta 0.21
  • Price/Sales 21.93
  • Price/Cash Flow N/A
  • Price/Book 3.63
Trade PRQR with:

Options Overview Details

View History
  • Implied Volatility 180.37% ( +30.64%)
  • Historical Volatility 79.28%
  • IV Percentile 51%
  • IV Rank 20.10%
  • IV High 804.33% on 06/26/23
  • IV Low 23.38% on 08/16/23
  • Put/Call Vol Ratio 0.49
  • Today's Volume 61
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 8,187
  • Open Int (30-Day) 8,058

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.12
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8100 +10.50%
on 04/18/24
2.5899 -22.78%
on 03/20/24
-0.5100 (-20.32%)
since 03/19/24
3-Month
1.7000 +17.65%
on 01/22/24
2.7000 -25.93%
on 03/15/24
-0.0800 (-3.85%)
since 01/19/24
52-Week
1.1100 +80.18%
on 10/27/23
3.2900 -39.21%
on 01/17/24
-0.2300 (-10.31%)
since 04/19/23

Most Recent Stories

More News
ProQR: Q3 Earnings Snapshot

ProQR: Q3 Earnings Snapshot

PRQR : 1.9800 (+6.45%)
ProQR: Q2 Earnings Snapshot

ProQR: Q2 Earnings Snapshot

PRQR : 1.9800 (+6.45%)
ProQR: Q1 Earnings Snapshot

ProQR: Q1 Earnings Snapshot

PRQR : 1.9800 (+6.45%)
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VCEL : 43.24 (-1.41%)
PRQR : 1.9800 (+6.45%)
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DTIL : 9.86 (-8.02%)
PRQR : 1.9800 (+6.45%)
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STRO : 3.61 (-4.24%)
PRQR : 1.9800 (+6.45%)
Will ProQR (PRQR) Report Negative Q1 Earnings? What You Should Know

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRQR : 1.9800 (+6.45%)
Why Shares of ProQR Therapeutics Dropped on Wednesday

The clinical-stage biotech released fourth-quarter and full-year earnings.

LLY : 727.14 (-2.52%)
PRQR : 1.9800 (+6.45%)
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

LLY : 727.14 (-2.52%)
GILD : 66.45 (+0.44%)
PRQR : 1.9800 (+6.45%)
ACER : 0.6601 (-17.95%)
KALA : 6.65 (-2.35%)
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

LLY : 727.14 (-2.52%)
PRQR : 1.9800 (+6.45%)
ASLN : 0.5210 (-3.52%)
IMCR : 55.31 (+1.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the...

See More

Key Turning Points

3rd Resistance Point 2.2433
2nd Resistance Point 2.1467
1st Resistance Point 2.0033
Last Price 1.9800
1st Support Level 1.7633
2nd Support Level 1.6667
3rd Support Level 1.5233

See More

52-Week High 3.2900
Fibonacci 61.8% 2.4572
Fibonacci 50% 2.2000
Last Price 1.9800
Fibonacci 38.2% 1.9428
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar